FDA Commissioner Dr Martin Makary took the stage at BIO 2025 to detail the way he and his team have been challenging “deeply ...

Eli Lilly has confirmed plans for a $1.3 billion takeover bid for Verve Therapeutics, upgrading a collaboration between the ...

Factor XIIa inhibitor Andembry (garadacimab) has been cleared in the US for use in patients aged 12 and over with HAE, which ...

The IPO comes just a few weeks after Caris raised $168 million in a private financing round that took the total raised by the ...

Other appointments to BIO's board for the 2025 through 2026 term include: Arcutis Bio's Frank Watanabe, named vice-chair; ...

Dr Lindborg shares her journey to her present role, the true potential shown in this new data for addressing unmet needs in ...

The Information Commissioner's Office (ICO) has levied a £2.31 million ($3.13 million) penalty on the Californian company in connection with a cyberattack in 2023 that resulted in the personal ...

That challenge, of finding or building good, useable data sets, is also one of the biggest differentiators in an increasingly ...

Streeting has also promised to reduce the time it takes to get clinical trials approved by cutting red tape, pointing out ...

Jeremy Skillington, CEO of LSE-listed Poolbeg Pharma, which has programmes targeting areas of high unmet medical need, ...

The annual conference of the Biotechnology Innovation Organization (BIO) is always an anticipated gathering where pharma and ...

Johnson & Johnson has new data showing that combining two of its multiple myeloma therapies – Talvey and Tecvayli – has been ...